Extracorporeal Membrane Oxygenation in Children With COVID-19: A Systematic Review and Meta-Analysis*
Authors:
- 17 November 2022
- journal article
- review article
- Published by Wolters Kluwer Health in Pediatric Critical Care Medicine
- Vol. 24 (5) , 406-416
Abstract
OBJECTIVES: The indication, complications, and outcomes of extracorporeal membrane oxygenation (ECMO) in children with COVID-19–related illnesses remain unelucidated. Our study aimed to investigate the characteristics and outcomes of ECMO in children with COVID-19–related illnesses. DATA SOURCES: We searched PubMed and EMBASE databases in March 2022. STUDY SELECTION: We retrieved all studies involving children (age ≤ 18 yr) with COVID-19–related illnesses who received ECMO. DATA EXTRACTION: Two authors independently extracted data and assessed the risk of bias. Mortality, successful weaning rate, and complications while on ECMO were synthesized by a one-group meta-analysis using a random-effect model. Meta-regression was performed to explore the risk factors for mortality. DATA SYNTHESIS: We included 18 observational studies, four case series, and 22 case reports involving 110 children with COVID-19–related illnesses receiving ECMO. The median age was 8 years (range, 10 d to 18 yr), and the median body mass index was 21.4 kg/m2 (range, 12.3–56.0 kg/m2). The most common comorbidities were obesity (11% [7/63]) and congenital heart disease (11% [7/63]), whereas 48% (30/63) were previously healthy. The most common indications for ECMO were multisystem inflammatory syndrome in children (52% [47/90]) and severe acute respiratory distress syndrome (40% [36/90]). Seventy-one percent (56/79) received venoarterial-ECMO. The median ECMO runtime was 6 days (range, 3–51 d) for venoarterial ECMO and 11 days (range, 3–71 d) for venovenous ECMO. The mortality was 26.6% (95% CI, 15.9–40.9), and the successful weaning rate was 77.0% (95% CI, 55.4–90.1). Complications were seen in 37.0% (95% CI, 23.1–53.5) while on ECMO, including stroke, acute kidney injury, pulmonary edema, and thromboembolism. Corticosteroids and IV immunoglobulin therapies were associated with lower mortality. CONCLUSIONS: The mortality of children on ECMO for COVID-19 was relatively low. This invasive treatment can be considered as a treatment option for critically ill children with COVID-19.Keywords
This publication has 64 references indexed in Scilit:
- Multisystem Inflammatory Syndrome in Children Associated with Severe Acute Respiratory Syndrome Coronavirus 2 Infection (MIS-C): A Multi-institutional Study from New York CityThe Journal of Pediatrics, 2020
- Characteristics and Outcomes of Children With Coronavirus Disease 2019 (COVID-19) Infection Admitted to US and Canadian Pediatric Intensive Care UnitsJAMA Pediatrics, 2020
- Acute Heart Failure in Multisystem Inflammatory Syndrome in Children in the Context of Global SARS-CoV-2 PandemicCirculation, 2020
- Veno-venous extracorporeal membrane oxygenation for COVID-19-associated pediatric acute respiratory distress syndromePerfusion, 2020
- Severe and fatal forms of COVID-19 in childrenArchives de Pédiatrie, 2020
- Extracorporeal Membrane OxygenationJAMA, 2020
- The Epidemiology of Severe Acute Respiratory Syndrome Coronavirus 2 in a Pediatric Healthcare Network in the United StatesJournal of the Pediatric Infectious Diseases Society, 2020
- ECMO use in COVID-19: lessons from past respiratory virus outbreaks—a narrative reviewCritical Care, 2020
- Assessing risk of bias in prevalence studies: modification of an existing tool and evidence of interrater agreementJournal of Clinical Epidemiology, 2012
- Bias in meta-analysis detected by a simple, graphical testBMJ, 1997